Tedor Pharma

Executive Summary

Tedor Pharma is a privately held contract development and manufacturing organization (CDMO) based in Princeton, NJ, founded in 2016. The company specializes in the reliable manufacture of high-quality solid dose pharmaceuticals and controlled substances, supporting clients from early-stage IND/NDA/ANDA through to commercial production. With a focus on speed, quality, and efficiency, Tedor Pharma offers comprehensive and flexible services tailored to the rigorous demands of the pharmaceutical industry. The company's expertise in handling controlled substances positions it uniquely in the CDMO landscape, enabling it to serve a niche but critical segment of drug development and manufacturing. As a CDMO, Tedor Pharma benefits from the growing trend of pharmaceutical outsourcing, particularly for complex formulations and controlled substances. The company's established capabilities and regulatory compliance provide a stable revenue base, though growth is driven by capacity expansion and strategic partnerships. Tedor's ability to navigate DEA regulations and deliver consistent quality makes it an attractive partner for both emerging biotechs and established pharma companies. While lacking near-term binary catalysts typical of drug developers, the company's steady operational expansion and client wins underpin a moderate conviction outlook. Key upcoming catalysts include FDA/DEA approvals for new manufacturing lines and partnerships with large pharmaceutical firms.

Upcoming Catalysts (preview)

• Q3 2026DEA Approval for New Controlled Substances Manufacturing Line80% success
• Q4 2026Strategic Partnership with Major Pharma for Schedule II-V Drug Production70% success
• Q2 2026Completion of Facility Expansion for Increased Solid Dose Capacity85% success